Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)ESMO Open 2022 Nov 07;7(6)100601, M Schmidt, K Lübbe, T Decker, M Thill, L Bauer, V Müller, T Link, J Furlanetto, M Reinisch, C Mundhenke, O Hoffmann, MO Zahn, L Müller, C Denkert, M van Mackelenbergh, PA Fasching, N Burchardi, V Nekljudova, S Loibl
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.